Comprehensive Report: Suvorexant (Belsomra)

Executive Summary & Drug Profile

Overview and Place in Therapy

Suvorexant, developed and produced by Merck & Co. under the brand name Belsomra, is a first-in-class small-molecule hypnotic agent.[1] It represents a significant advancement in the pharmacotherapy of sleep disorders, belonging to a novel class of drugs known as dual orexin receptor antagonists (DORAs).[2] Its primary indication is for the treatment of insomnia in adults, specifically addressing difficulties with both sleep onset (falling asleep) and sleep maintenance (staying asleep).[1]

The therapeutic distinction of suvorexant lies in its unique mechanism of action. Unlike traditional hypnotics that induce global central nervous system (CNS) depression, suvorexant selectively targets and inhibits the orexin neuropeptide system, a key regulator of wakefulness and arousal in the brain.[7] By suppressing the "wake drive," suvorexant facilitates the natural transition to sleep rather than inducing sedation through broad inhibitory pathways.[4] This targeted approach offers a different risk-benefit profile compared to older agents, particularly concerning the potential for physical dependence and withdrawal.

In the United States, suvorexant is regulated as a Schedule IV controlled substance by the Drug Enforcement Administration (DEA), a classification that reflects a recognized medical use and a low potential for abuse and dependence relative to substances in Schedule III.[9] Its introduction has provided clinicians with an alternative for patients who cannot tolerate or do not receive adequate benefit from traditional sleep agents, such as benzodiazepine receptor agonists.[3]

Chemical and Physical Properties

Suvorexant is a synthetic organic compound with a complex molecular structure that includes several heterocyclic rings. Chemically, it is classified as an aromatic amide and is a member of the 1,3-benzoxazole, 1,2,3-triazole, and 1,4-diazepane families of compounds.[11] The molecule contains a single chiral center, with the specified stereochemistry being crucial for its pharmacological activity.[12]

The formal International Union of Pure and Applied Chemistry (IUPAC) name for the active enantiomer is[5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone.[1] Its molecular formula is

C23​H23​ClN6​O2​, corresponding to a molecular weight of approximately 450.93 g/mol.[4] The compound is identified by the Chemical Abstracts Service (CAS) Registry Number 1030377-33-3 and the DrugBank Accession Number DB09034.[1] The molecular structure can be uniquely represented by the Simplified Molecular Input Line Entry System (SMILES) string: C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl.[9]

Table 1: Suvorexant Key Drug Information Summary

Property	Value
Generic Name	Suvorexant
Brand Name	Belsomra®
Drug Class	Dual Orexin Receptor Antagonist (DORA); Hypnotic; Sedative
DrugBank ID	DB09034
CAS Number	1030377-33-3
Molecular Formula	C23​H23​ClN6​O2​
Molecular Weight	~450.93 g/mol
FDA Approval Date	August 13, 2014
CSA Schedule	Schedule IV

The Orexin System and the Pharmacodynamics of Suvorexant

The Orexin/Hypocretin System: The Central Regulator of Wakefulness

The mechanism of action of suvorexant is inextricably linked to the neurobiology of the orexin system, a critical regulator of the sleep-wake cycle. The orexin system, also known as the hypocretin system, is composed of two neuropeptides, Orexin-A (hypocretin-1) and Orexin-B (hypocretin-2).[8] These peptides are produced by a discrete population of approximately 70,000 neurons located exclusively within the lateral and perifornical areas of the hypothalamus.[4]

Despite their localized origin, these orexin neurons project widely throughout the central nervous system. Their primary function is to promote and sustain wakefulness by activating key arousal centers in the brainstem and hypothalamus. These centers include the noradrenergic locus coeruleus, the histaminergic tuberomammillary nucleus, the dopaminergic ventral tegmental area, and cholinergic nuclei.[3] By releasing orexins, these neurons provide a powerful excitatory signal that maintains a consolidated state of arousal. The orexin system acts as a master integrator, responding to metabolic cues (such as hunger), circadian rhythms, and homeostatic sleep pressure to determine an organism's state of vigilance.[8] Clinical evidence underscores its pivotal role: a deficiency in orexin signaling due to the loss of these neurons is the primary cause of narcolepsy, a disorder characterized by excessive daytime sleepiness and an unstable sleep-wake state.[3] Conversely, hyperactivity of the orexin system is hypothesized to be a key pathophysiological driver of insomnia.[8]

Mechanism of Action: Dual Orexin Receptor Antagonism

Suvorexant exerts its therapeutic effect by acting as a potent, selective, and competitive dual antagonist of the two orexin receptor subtypes, the orexin-1 receptor (OX1​R) and the orexin-2 receptor (OX2​R).[2] Orexin-A binds with high affinity to both

OX1​R and OX2​R, whereas Orexin-B binds preferentially to OX2​R.[14] By competitively blocking both receptor subtypes, suvorexant prevents the binding of endogenous orexin neuropeptides, thereby inhibiting their wake-promoting signals.[3]

This mechanism represents a fundamental paradigm shift in insomnia treatment. Rather than actively inducing sleep through widespread neuronal inhibition, suvorexant works by suppressing the central "wake drive".[4] This allows the brain's natural sleep-promoting systems to take over, facilitating a more physiological transition from wakefulness to sleep.[7] This targeted suppression of arousal is thought to be the key to its clinical effects on both sleep onset and maintenance.

Pharmacodynamic Distinction from GABAergic Agents

The pharmacodynamic profile of suvorexant is fundamentally different from that of traditional hypnotics, such as benzodiazepines (e.g., temazepam) and non-benzodiazepine "Z-drugs" (e.g., zolpidem). These older agents exert their effects by acting as positive allosteric modulators of the gamma-aminobutyric acid type A (GABAA​) receptor, the primary inhibitory neurotransmitter receptor in the brain.[1] Potentiation of GABAergic signaling leads to widespread CNS depression, which is responsible for their sedative effects.[8]

Suvorexant does not interact with GABA receptors.[1] This distinction is clinically profound. The global CNS depression induced by GABAergic agents is mechanistically linked to their classic adverse effect profile, which includes significant psychomotor impairment, ataxia, anterograde amnesia, and the risk of respiratory depression, especially when combined with other CNS depressants.[14] Furthermore, chronic modulation of the GABA system can lead to receptor downregulation and neuroadaptive changes, which underlie the development of physical dependence, tolerance, and withdrawal phenomena, including rebound insomnia upon discontinuation.[17]

By targeting the highly localized orexin system, suvorexant avoids this widespread inhibitory action. This targeted mechanism is the neurobiological basis for its more favorable profile regarding physical dependence and withdrawal, which were not found to be clinically significant in trials.[1] This allows suvorexant to reduce arousal without causing the same degree of global CNS depression associated with older hypnotics.

Impact on Sleep Architecture

Suvorexant has a unique and notable impact on the architecture of sleep. In contrast to most other hypnotics, which typically suppress or have no effect on rapid eye movement (REM) sleep, orexin receptor antagonists increase total sleep time primarily by increasing the duration of REM sleep.[1] The effect on non-rapid eye movement (NREM) sleep is neutral or may even involve a slight decrease.[1]

This pharmacodynamic effect on sleep stages is not merely an academic observation; it has direct clinical implications. REM sleep is critical for functions such as memory consolidation, emotional processing, and learning. While an increase in this sleep stage could theoretically be beneficial, it also provides a plausible physiological basis for one of suvorexant's most frequently reported side effects: abnormal or vivid dreams and nightmares.[1] The pharmacologically induced increase in the duration and potentially the density of REM sleep, the stage most associated with dreaming, likely underlies the subjective patient experience of more intense or frequent dreams. This suggests that this particular side effect is not an idiosyncratic reaction but rather an expected, mechanism-based outcome of the drug's action on sleep architecture. This understanding is crucial for effective patient counseling, helping to manage expectations and contextualize potential adverse experiences.

Clinical Pharmacology: A Pharmacokinetic Profile

Absorption and Distribution

The pharmacokinetic profile of suvorexant is well-characterized, providing the basis for its dosing recommendations and interaction profile. Following oral administration, suvorexant is readily absorbed, exhibiting a high mean absolute bioavailability of 82% at the 10 mg dose.[1] Under fasted conditions, peak plasma concentrations (

Tmax​) are achieved at a median of 2 hours, although there is considerable inter-individual variability, with a range of 30 minutes to 6 hours.[4]

The presence of food, particularly a high-fat meal, significantly impacts the rate of absorption. While co-administration with food does not meaningfully alter the overall drug exposure (Area Under the Curve, AUC) or the peak concentration (Cmax​), it can delay the Tmax​ by approximately 1.5 hours.[1] This delay in reaching peak levels can translate to a slower onset of sleep, which underlies the clinical recommendation to administer suvorexant on an empty stomach if a more rapid effect is desired.[3] Over a dose range of 10 mg to 80 mg, suvorexant exposure increases in a less-than-proportional manner, which is attributed to decreased absorption at higher doses.[1]

Once absorbed, suvorexant is extensively distributed. It is highly bound to human plasma proteins (>99%), primarily to albumin and alpha1-acid glycoprotein.[4] The mean volume of distribution is approximately 49 liters, indicating that the drug distributes into tissues beyond the plasma volume.[4]

Metabolism and Elimination

Suvorexant is cleared from the body primarily through extensive metabolism. The major metabolic pathway is mediated by the cytochrome P450 enzyme system, with CYP3A4 being the principal enzyme responsible for its biotransformation and a minor contribution from CYP2C19.[3] This heavy reliance on CYP3A4 makes suvorexant highly susceptible to drug-drug interactions with inhibitors or inducers of this enzyme. The primary circulating metabolite is hydroxy-suvorexant, which is considered pharmacologically inactive; therefore, the clinical effects are attributable to the parent compound.[4]

Elimination of the drug and its metabolites occurs predominantly via the feces, which accounts for approximately 66% of an administered dose. A smaller fraction, about 23%, is excreted in the urine.[1] The mean terminal elimination half-life (

t1/2​) of suvorexant is approximately 12 hours, with a reported range of 8 to 19 hours.[1] This classifies suvorexant as an intermediate-acting hypnotic. This half-life is a critical determinant of its clinical profile; it is long enough to maintain therapeutic concentrations throughout a typical 7- to 8-hour sleep period, thereby addressing sleep maintenance insomnia, but it is also sufficiently long to potentially result in residual drug levels upon waking, which is the direct cause of its primary adverse effect, next-day somnolence.[1] With once-daily administration, steady-state plasma concentrations are achieved within 3 days, with minimal drug accumulation of approximately 1.2- to 1.6-fold.[1]

Influence of Patient Factors on Pharmacokinetics

Several intrinsic patient factors can significantly influence the pharmacokinetics of suvorexant, leading to variability in drug exposure and potentially affecting both efficacy and safety.

Gender and Body Mass Index (BMI): Clinical studies have demonstrated that suvorexant exposure is higher in females and in individuals with obesity (BMI > 30 kg/m²). Females exhibit a 9% to 17% increase in Cmax​ and AUC, respectively, compared to males.[3] Similarly, obese patients show a 17% to 31% increase in

Cmax​ and AUC compared to non-obese individuals.[5] These effects are additive and most pronounced in obese women, who can experience an increase in AUC of up to 46% and in

Cmax​ of up to 25%.[3] This substantial increase in drug exposure in a specific subpopulation creates a "hidden" high-risk group. For an obese female patient, a standard 20 mg dose could result in systemic exposure equivalent to a supratherapeutic dose in a non-obese male, thereby dramatically increasing her risk of experiencing dose-dependent adverse effects such as next-day impairment, falls, and narcolepsy-like symptoms. This finding underscores the inadequacy of a "one-size-fits-all" dosing strategy and highlights the critical importance of personalized dose titration, especially in this demographic.

Hepatic and Renal Impairment: Suvorexant's pharmacokinetics are not significantly altered by renal impairment, and no dose adjustment is necessary for patients with any degree of renal dysfunction, including severe impairment.[5] Similarly, no dose adjustment is required for patients with mild-to-moderate hepatic impairment (Child-Pugh category 7 to 9), although the apparent terminal half-life was observed to be prolonged in this group (approximately 19 hours vs. 15 hours in healthy subjects).[5] However, due to the lack of data and its extensive hepatic metabolism, the use of suvorexant is not recommended in patients with severe hepatic impairment.[7]

Clinical Efficacy and Therapeutic Application

Approved Indication and Efficacy Data

Suvorexant is approved by the U.S. Food and Drug Administration (FDA) and other international regulatory bodies for the treatment of insomnia in adults characterized by difficulties with sleep onset and/or sleep maintenance.[1] Its efficacy has been established in multiple large, randomized, placebo-controlled Phase III clinical trials.

In these pivotal trials, suvorexant demonstrated statistically significant superiority over placebo across a range of objective and subjective endpoints.[31] At approved doses of 15 mg to 20 mg, patient-reported (subjective) outcomes showed that suvorexant reduced the time to fall asleep (subjective time to sleep onset, sTSO) and increased the duration of sleep (subjective total sleep time, sTST).[1] The magnitude of these improvements, in terms of the difference from placebo, was approximately a 10-minute reduction in sleep onset time and a 10- to 20-minute increase in total sleep time.[1] Objective measures, assessed via in-laboratory polysomnography (PSG), confirmed these findings, showing significant reductions in wake time after persistent sleep onset (WASO) and latency to persistent sleep (LPS).[31]

A key finding from these trials was the sustained nature of suvorexant's efficacy. The improvements in sleep onset and maintenance were observed early in treatment (at Night 1 for PSG and Week 1 for subjective measures) and were maintained over longer periods, including at Month 1 and Month 3.[31] Furthermore, a 12-month extension study demonstrated continued benefit without evidence of the development of tolerance, and upon discontinuation, there was no clinically meaningful rebound insomnia or withdrawal symptoms.[33]

It is noteworthy that while the improvements in sleep parameters were statistically significant, the absolute gains in sleep duration over placebo were modest. This has led to a clinical observation that the FDA's approval, based on these data, may reflect an appreciation for benefits not fully captured by traditional endpoints like sTST. The drug's unique mechanism and its effect on increasing REM sleep may contribute to an improved subjective quality of sleep or a more restorative feeling upon waking, a "hidden" benefit that justifies its use despite small quantitative changes in sleep duration.

Dosage, Forms, and Administration

Suvorexant is supplied as film-coated oral tablets available in four strengths: 5 mg, 10 mg, 15 mg, and 20 mg.[25]

Standard Dosing: The recommended starting dose for most adults is 10 mg, to be taken no more than once per night.[19] The medication should be administered within 30 minutes of going to bed, and only when the patient has at least 7 hours remaining before their planned time of awakening to minimize the risk of next-day impairment.[21]

Dose Titration: The guiding principle for dosing is to use the lowest effective dose for the patient. If the initial 10 mg dose is well-tolerated but provides an insufficient clinical response, the dose can be increased. The maximum recommended dose is 20 mg once daily.[1] The FDA's decision to cap the maximum dose at 20 mg, despite higher doses (e.g., 30 mg and 40 mg) being studied and showing greater efficacy in clinical trials, reflects a critical regulatory balance between efficacy and safety.[7] The higher doses were associated with an unacceptable incidence of dose-dependent adverse effects, particularly next-day somnolence and driving impairment.[15] This regulatory action underscores the narrow therapeutic window of suvorexant and reinforces the clinical imperative to titrate cautiously, prioritizing safety.

Discontinuation: Clinical trial data suggest that suvorexant can be discontinued abruptly without tapering. After one year of continuous nightly use, abrupt cessation did not result in significant withdrawal symptoms or rebound insomnia beyond the expected return of baseline sleep difficulties.[7]

Dosing in Special Populations and Scenarios

Elderly Patients: While no specific dose adjustment is mandated based on age alone, a conservative approach is warranted. Treatment should be initiated at the lowest dose (10 mg), and clinicians should exercise caution due to the heightened risk of falls, cognitive impairment, and next-day somnolence in this population.[19] In the pivotal clinical trials, a lower dose was used for patients aged 65 and older (e.g., 15 mg instead of 20 mg), reflecting this cautious approach.[5]

Hepatic Impairment: No dosage adjustment is required for patients with mild or moderate hepatic impairment. However, suvorexant has not been studied in patients with severe hepatic impairment and is therefore not recommended for this population.[25]

Renal Impairment: Suvorexant's pharmacokinetics are not significantly affected by renal function. No dose adjustment is necessary for patients with any degree of renal impairment, including those with severe renal disease.[5]

Coadministration with CYP3A Inhibitors: Due to its primary metabolism by CYP3A4, dosage adjustments are critical when suvorexant is co-administered with drugs that inhibit this enzyme.

• Moderate CYP3A Inhibitors (e.g., diltiazem, verapamil, fluconazole): The recommended dose of suvorexant should be reduced to 5 mg once nightly. If this dose is tolerated but not effective, it may be increased, but should generally not exceed 10 mg.[22]
• Strong CYP3A Inhibitors (e.g., ketoconazole, itraconazole, clarithromycin): Co-administration is not recommended, as it can lead to a significant increase in suvorexant exposure and a heightened risk of adverse effects.[22]

Safety, Tolerability, and Risk Management

Common Adverse Events

The safety profile of suvorexant has been well-characterized through extensive clinical trials. The most common adverse event reported is somnolence, or daytime sleepiness, which occurred in approximately 7% of patients receiving suvorexant (15 mg or 20 mg) compared to 3% of patients receiving placebo.[7] This effect is dose-related and is the primary safety concern associated with the medication.

Other common adverse reactions, occurring in at least 2% of patients and at a higher rate than placebo, include headache, dizziness, abnormal dreams, and dry mouth.[1] Less frequently reported events include cough and diarrhea.[15] In a one-year extension study, the adverse event profile remained consistent with that observed in the initial 3-month trials.[15]

Key Warnings and Precautions (Boxed Warnings and Major Risks)

The prescribing information for suvorexant includes several significant warnings and precautions that are critical for safe clinical use.

CNS Depression and Next-Day Impairment: As a CNS depressant, suvorexant can impair daytime function, including alertness, motor coordination, and driving skills.[36] This impairment can occur even if the patient feels fully awake and may persist for several days after discontinuation.[4] The risk is dose-dependent and is significantly increased if the medication is taken with less than a full night of sleep remaining (at least 7 hours), if a higher-than-recommended dose is taken, or if it is co-administered with other CNS depressants like alcohol.[4] Patients receiving the 20 mg dose are specifically cautioned against driving or engaging in other activities that require full mental alertness the following day.[30]

Worsening of Depression and Suicidal Ideation: In clinical studies, a dose-dependent increase in suicidal ideation was observed in patients taking suvorexant, as assessed by questionnaires.[4] Like other sedative-hypnotics, suvorexant may cause or worsen depression. Therefore, it should be used with caution in patients with a history of depression, and any new or concerning behavioral changes, including suicidal thoughts, require immediate and careful evaluation.[1] This psychiatric risk may be more than a generic side effect; it could be mechanistically linked to the orexin system's broader role in regulating mood, motivation, and reward.[14] By dampening this system, suvorexant might inadvertently blunt the capacity for positive affect in vulnerable individuals, making thorough psychiatric screening a critical prerequisite to prescribing.

Complex Sleep Behaviors: The use of suvorexant has been associated with complex sleep behaviors, such as sleep-walking, sleep-driving, and engaging in other activities while not fully awake (e.g., preparing and eating food, making phone calls, having sex), often with amnesia for the event.[1] These events can be dangerous and can occur in both new and experienced users. The risk is elevated by concomitant use of alcohol or other CNS depressants. If a patient experiences a complex sleep behavior, suvorexant should be discontinued immediately.[36]

Narcolepsy-Like Symptoms: A unique set of adverse effects associated with suvorexant stems directly from its mechanism of action. By antagonizing the orexin system, the drug can pharmacologically induce a temporary state that mimics the symptoms of narcolepsy, a condition caused by orexin deficiency.[15] These rare but notable symptoms include:

• Sleep Paralysis: A transient inability to move or speak for several minutes during the transition between sleep and wakefulness.[1]
• Hypnagogic/Hypnopompic Hallucinations: Vivid, often disturbing, dream-like perceptions that occur while falling asleep or waking up.[1]
• Cataplexy-Like Symptoms: Brief, sudden episodes of leg weakness, which can be triggered by emotion.[4]

The occurrence of these symptoms is a direct manifestation of the drug's intended pharmacological action and underscores the critical importance of the contraindication in patients with diagnosed narcolepsy.

Contraindications and High-Risk Populations

Narcolepsy: Suvorexant is absolutely contraindicated in patients with narcolepsy.[6] Administering an orexin antagonist to a patient with an already deficient orexin system would be expected to severely exacerbate their symptoms.

Compromised Respiratory Function: Caution is advised when prescribing suvorexant to patients with compromised respiratory function, such as those with severe chronic obstructive pulmonary disease (COPD) or obstructive sleep apnea (OSA). The effects of suvorexant have not been formally evaluated in these specific populations.[19]

History of Substance Abuse: Suvorexant is a Schedule IV controlled substance. Studies in recreational polydrug users have shown that at supratherapeutic doses (40 mg, 80 mg, and 150 mg), suvorexant produced subjective "drug liking" scores similar to those of zolpidem (15 mg and 30 mg).[7] This indicates a potential for misuse and psychological dependence. Therefore, it should be prescribed with caution to individuals with a history of alcohol or other substance use disorders.[1]

Pregnancy and Lactation: Suvorexant is classified as Pregnancy Category C in the United States and Category B3 in Australia.[1] Animal studies have shown teratogenic effects, such as decreased fetal body weight, at doses significantly higher than those used in humans.[1] There are no adequate and well-controlled studies in pregnant women. Very low amounts of suvorexant are excreted into human breast milk, with the relative infant dose estimated to be less than 1% of the maternal dose.[46] While breastfeeding is not an absolute reason to discontinue the medication if required by the mother, the infant should be monitored for sedation. Alternative hypnotics with more established safety profiles in lactation, such as zaleplon or zolpidem, may be considered.[46]

Drug Interaction Profile

Pharmacodynamic Interactions (Additive CNS Depression)

The most significant pharmacodynamic interactions with suvorexant involve its additive effects with other CNS depressants. Co-administration can potentiate sedation, cognitive and psychomotor impairment, and increase the risk of adverse outcomes.

Alcohol and Other CNS Depressants: The concomitant use of suvorexant with alcohol is strongly discouraged due to potentially severe additive effects on CNS depression.[24] Similarly, caution and potential dosage adjustments are necessary when suvorexant is taken with other CNS depressants, including benzodiazepines, opioids, tricyclic antidepressants, muscle relaxers, and certain antihistamines.[19] The use of suvorexant with other medications indicated for insomnia, such as zolpidem or eszopiclone, is not recommended due to the high risk of additive pharmacodynamic effects and next-day impairment.[47]

Pharmacokinetic Interactions (CYP3A4-Mediated)

Suvorexant's heavy reliance on the CYP3A4 enzyme for its metabolism makes it highly susceptible to pharmacokinetic drug-drug interactions. This single metabolic vulnerability means that a wide array of common medications can significantly alter suvorexant plasma concentrations, leading to either toxicity or loss of efficacy. This makes a thorough medication reconciliation, including over-the-counter products and supplements, an essential safety measure before initiating therapy.

CYP3A4 Inhibitors:

• Strong Inhibitors: Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin) can cause a substantial increase in suvorexant exposure and is not recommended.[23]
• Moderate Inhibitors: When used with moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, fluconazole, erythromycin), suvorexant exposure is also significantly increased. In this scenario, the recommended starting dose of suvorexant should be reduced to 5 mg, with a maximum dose not to exceed 10 mg.[22]

CYP3A4 Inducers:

• Strong Inducers: Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, and the herbal supplement St. John's wort) can markedly decrease suvorexant plasma levels, potentially leading to a loss of therapeutic effect.[25]

Acetaminophen: An interaction of subtle but notable clinical importance is with acetaminophen. The metabolism of suvorexant can be increased when combined with acetaminophen, which may lead to reduced efficacy.[4] Given the ubiquitous use of acetaminophen as an over-the-counter analgesic, patients may not report its use. If a patient on suvorexant reports a gradual loss of effect, clinicians should specifically inquire about frequent acetaminophen use before assuming the development of tolerance.

Other Notable Interactions

Digoxin: Suvorexant is a weak inhibitor of the intestinal efflux transporter P-glycoprotein (P-gp). Co-administration with digoxin, a P-gp substrate with a narrow therapeutic index, can cause a slight increase in digoxin levels. Therefore, it is recommended that digoxin concentrations be monitored when initiating therapy with suvorexant.[22]

Grapefruit Juice: Grapefruit and its juice are potent inhibitors of intestinal CYP3A4. Consumption should be avoided during treatment with suvorexant, as it can significantly increase plasma concentrations of the drug and heighten the risk of dose-related side effects.[24]

Comparative Analysis in the Hypnotic Landscape

Suvorexant vs. GABAergic Agents (Zolpidem, Temazepam)

Suvorexant's place in therapy is best understood by comparing it to the long-standing gold standards, the GABAergic agents.

Mechanism and Effects: The core difference is the mechanism: suvorexant suppresses wakefulness via orexin antagonism, while zolpidem and temazepam enhance global inhibition via GABA-A receptor modulation.[8] This leads to different clinical profiles. Immediate-release zolpidem generally has a faster onset of action, making it a potential choice for sleep-onset insomnia, whereas suvorexant's 12-hour half-life makes it well-suited for sleep maintenance.[17]

Safety and Tolerability: Suvorexant offers a theoretical long-term safety advantage due to a lower reported risk of physical dependence, withdrawal, and rebound insomnia upon discontinuation.[1] In contrast, benzodiazepines like temazepam are associated with a higher risk of dependence and are classified as Pregnancy Category X, a more restrictive category than suvorexant's Category C.[51] However, suvorexant introduces a unique set of adverse effects, including narcolepsy-like symptoms and a higher incidence of abnormal dreams and nightmares.[1]

Patient Preference and Abuse Potential: A stark contradiction exists between the theoretical safety benefits of suvorexant and real-world patient satisfaction. User ratings on platforms like Drugs.com show a strong preference for temazepam (average rating 6.5/10) over suvorexant (3.9/10).[51] This suggests that for a substantial portion of patients, the immediate and predictable efficacy of older agents, coupled with a familiar side effect profile, is preferred over the novel mechanism of suvorexant, which can be less effective for sleep onset and may produce more bothersome neuropsychiatric side effects. This highlights that "safety" is a multifaceted concept; while suvorexant may be safer from a dependence standpoint, its day-to-day tolerability may be perceived as worse by many users. Regarding abuse potential, both suvorexant and zolpidem are Schedule IV substances, and a head-to-head abuse liability study found that high doses of suvorexant produced "drug liking" scores comparable to zolpidem, validating its controlled status.[7]

Suvorexant vs. Next-Generation DORAs (Lemborexant, Daridorexant)

The DORA class is not monolithic; the three FDA-approved agents are primarily differentiated by their pharmacokinetic profiles, which in turn dictate their specific clinical characteristics.

Pharmacokinetics as the Key Differentiator: The most significant difference among the DORAs is their elimination half-life. This single parameter is the main driver of their distinct risk-benefit profiles and allows for a more personalized approach to treatment.

• Daridorexant (Quviviq): Has the shortest half-life at approximately 8 hours.[53] This profile is designed to minimize the risk of next-day impairment and residual somnolence, making it a potentially suitable option for patients who are highly sensitive to "hangover" effects or who have demanding next-day responsibilities.
• Suvorexant (Belsomra): Occupies the middle ground with a half-life of approximately 12 hours.[1] This provides a balance between efficacy for sleep maintenance throughout the night and a manageable risk of next-day effects for many patients.
• Lemborexant (Dayvigo): Possesses the longest effective half-life at 17-19 hours.[53] This extended duration of action may offer the most robust efficacy for patients with severe sleep maintenance insomnia or early morning awakenings, but it also carries the highest theoretical risk of next-day drowsiness and functional impairment.

Efficacy and Safety: Network meta-analyses have attempted to compare the three agents indirectly. The results suggest subtle differences in efficacy: lemborexant may be superior for subjective sleep onset, while suvorexant and daridorexant are highly effective for objective sleep latency.[55] All three are effective in reducing wakefulness after sleep onset.[55] In terms of safety, all DORAs share class effects like somnolence. Some analyses suggest daridorexant may have a higher risk of overall treatment-emergent adverse events, while lemborexant may have a higher risk of treatment-related adverse events and somnolence specifically.[57] Suvorexant was noted to have the highest risk of excessive daytime sleepiness occurrence compared to placebo in one meta-analysis.[58] Importantly, long-term extension studies for the class have generally not shown a loss of efficacy over time, a key advantage over older hypnotics.[59]

Table 2: Comparative Profile of Suvorexant vs. Other Key Hypnotics

Feature	Suvorexant (Belsomra)	Zolpidem (Ambien)	Temazepam (Restoril)	Lemborexant (Dayvigo)	Daridorexant (Quviviq)
Mechanism of Action	Dual Orexin Receptor Antagonist (DORA)	GABAA​ Receptor Agonist	GABAA​ Receptor Agonist (Benzodiazepine)	Dual Orexin Receptor Antagonist (DORA)	Dual Orexin Receptor Antagonist (DORA)
Half-Life (approx.)	12 hours	2-3 hours (IR)	16 hours	17-19 hours	8 hours
Primary Efficacy	Sleep Onset & Maintenance	Sleep Onset (IR); Onset & Maintenance (CR)	Sleep Onset & Maintenance	Sleep Onset & Maintenance	Sleep Onset & Maintenance
Key Adverse Effects	Somnolence, abnormal dreams, headache, narcolepsy-like symptoms	Drowsiness, dizziness, headache, complex sleep behaviors	Drowsiness, hangover effect, dizziness, confusion	Somnolence, headache, nightmares	Headache, somnolence, fatigue
Abuse/Dependence	Low (Schedule IV)	Moderate (Schedule IV); Risk of dependence/withdrawal	Moderate-High (Schedule IV); High risk of dependence/withdrawal	Low (Schedule IV)	Low (Schedule IV)
Relative Cost	High (Brand only)	Low (Generic available)	Low (Generic available)	High (Brand only)	High (Brand only)

Real-World Evidence and Patient-Reported Outcomes

Post-Marketing Surveillance Data

Beyond the controlled setting of clinical trials, real-world evidence provides crucial context for a drug's performance in a broader, more heterogeneous patient population. A large-scale post-marketing surveillance survey conducted in Japan, involving over 3,200 patients newly treated with suvorexant, offers valuable insights.[60]

The survey found that suvorexant was both effective and generally well-tolerated in daily clinical practice. A high rate of clinical improvement, as assessed by both patients and their physicians, was observed across all age groups, with 70-75% of patients reporting benefit.[60] Notably, the study included a large cohort of elderly patients (n=1,758 aged ≥65), many with multiple comorbidities. In this vulnerable population, the safety profile was favorable. The overall incidence of adverse drug reactions (ADRs) was found to be lower in the older age groups (8.6% in ages 65-74 and 8.2% in ages ≥75) compared to the non-elderly group (11.3% in ages <65).[60] The most common ADRs were consistent with the clinical trial data—somnolence, dizziness, and paradoxical insomnia—and no new safety signals were identified. These findings suggest that in a real-world Japanese clinical setting, suvorexant maintains a positive risk-benefit profile, even in complex elderly patients.

Synthesis of Patient Experiences from Online Forums

In stark contrast to the formal post-marketing data, qualitative patient-reported outcomes from Western online forums and review sites like Drugs.com and WebMD paint a much more polarized and often negative picture. Aggregate user ratings for suvorexant are consistently low, with a large majority of reviewers (approximately 61%) reporting a negative experience, while a smaller but vocal minority (around 27%) report highly positive, sometimes life-changing, outcomes.[62]

Positive Themes: Patients who respond well to suvorexant frequently praise its unique quality of action. They often describe the experience as a "natural" drift into sleep, contrasting it favorably with the heavy sedation or "knocked out" feeling associated with GABAergic agents.[62] Many successful users highlight its efficacy in maintaining sleep throughout the night and report waking up feeling refreshed and without a "hangover".[62] Some experienced users note that the drug's effectiveness is enhanced after a "wash-out" period from other hypnotics, suggesting that prior exposure to GABAergic drugs may initially blunt its effect.[62]

Negative Themes: The negative reviews are dominated by two primary complaints. The first is a complete lack of efficacy, with many users stating the drug "did nothing" to help them sleep.[62] The second, and more concerning, is the high incidence of severe and disturbing neuropsychiatric side effects. These reports frequently describe intense and frightening nightmares, sleep paralysis, and hypnagogic hallucinations.[62] A recurring and critical theme in these negative experiences is the emergence or exacerbation of next-day anxiety, depression, and in some cases, suicidal ideation, particularly in individuals with a pre-existing psychiatric history.[64]

The significant disconnect between the positive findings of the formal Japanese survey and the predominantly negative sentiment in informal Western forums is striking. This discrepancy may stem from various factors, including cultural differences in reporting adverse events, different prescribing patterns, varying patient expectations, or the inherent self-selection bias of online forums, where individuals with strong negative experiences may be more motivated to share their stories. This contradiction underscores the complexity of interpreting real-world evidence and suggests that while many patients may benefit, a substantial subgroup experiences significant distress, a risk that may be underrepresented in formal surveillance studies. The strong pattern of psychiatric side effects in patient reviews also serves as powerful real-world validation of the mechanistic link between orexin system modulation and mood regulation, reinforcing the clinical need for careful psychiatric screening before prescribing suvorexant.

Emerging Research and Future Directions

Suvorexant in Neurodegenerative and Psychiatric Disorders

The therapeutic investigation of suvorexant and the broader DORA class is expanding beyond primary insomnia, with significant research focused on patient populations where sleep disturbance is a prominent secondary feature of a complex underlying disorder.

Alzheimer's Disease (AD): The orexin system's role in AD is an area of intense investigation, positioning suvorexant as a drug with dual potential for symptomatic relief and possible disease modification.

• Symptomatic Treatment: Sleep disturbances and nocturnal agitation are common and debilitating symptoms in AD. A Phase III clinical trial demonstrated that suvorexant significantly improved objective measures of total sleep time and wake after sleep onset in patients with mild-to-moderate AD and insomnia.[67] Furthermore, multiple case reports and preliminary studies suggest that suvorexant may be effective in managing nocturnal delirium and agitation in this population, possibly by stabilizing the sleep-wake cycle.[69] Some evidence points to a greater benefit for hyperactive and mixed delirium subtypes over hypoactive delirium.[71]
• Disease Modification Potential: The most groundbreaking research involves suvorexant's potential impact on the core pathophysiology of AD. A small but rigorous study in healthy, middle-aged adults found that two nights of suvorexant administration led to an acute, temporary reduction in the cerebrospinal fluid (CSF) levels of key AD biomarkers: amyloid-beta (a 10-20% decrease) and phosphorylated tau (a 10-15% decrease).[73] This finding provides the first human evidence for a mechanistic link between improving sleep via orexin antagonism and the clearance of the pathogenic proteins that form plaques and tangles. This elevates the treatment of insomnia in at-risk individuals from a quality-of-life issue to a potential neuroprotective strategy, representing a possible paradigm shift in how sleep is managed in the context of neurodegeneration.

Bipolar Depression: Insomnia is a cardinal symptom of bipolar depression and can be a predictor of relapse. A Phase IV clinical trial was conducted to evaluate suvorexant as an adjunctive therapy for patients with bipolar depression and co-occurring insomnia, exploring its potential to improve both sleep and mood symptoms in this challenging-to-treat population.[75]

Opioid Use Disorder (OUD): Sleep disruption is a severe component of opioid withdrawal that can contribute to relapse. Preclinical data and early human studies have shown that suvorexant can not only ameliorate sleep disturbances during opioid taper but also reduce subjective withdrawal symptoms and craving.[76] These promising initial results have led to the launch of a large, multi-site Phase III trial to definitively assess suvorexant's efficacy and safety in patients undergoing treatment for OUD.[76]

Other Investigational Areas

The potential applications of suvorexant are being explored in other populations where insomnia is a significant comorbidity.

• Cancer Survivors: Many cancer survivors, particularly breast cancer patients on endocrine therapy, experience persistent insomnia that negatively impacts their quality of life. Active clinical trials are investigating the efficacy of suvorexant in this population, with primary outcomes focused on improvements in sleep and overall quality of life.[77]
• Fibromyalgia: The bidirectional relationship between pain and poor sleep is well-established. A clinical study was designed to assess whether improving sleep with suvorexant could, in turn, reduce pain sensitivity and daytime fatigue in patients with fibromyalgia and co-morbid insomnia.[79]

The Broader Orexin System: A Target for Future Therapeutics

The success of suvorexant has catalyzed broader interest in the orexin system as a therapeutic target for a range of disorders beyond sleep.

• Appetite and Metabolism: The orexin system was originally named for its role in stimulating appetite (from the Greek orexis).[80] It is now understood to be a key regulator of energy homeostasis, reward-seeking for palatable foods, and lipid metabolism.[81] This opens the possibility of developing orexin receptor modulators for the treatment of obesity, binge eating disorder, and other metabolic syndromes.[81]
• Mood and Addiction: The dense projections of orexin neurons to key reward and emotion centers, such as the ventral tegmental area and nucleus accumbens, firmly implicate the system in the neurobiology of mood disorders and addiction.[43] Orexin signaling is involved in stress responses and motivation for drug-seeking. Consequently, orexin antagonists are being actively investigated as potential treatments to prevent relapse in substance use disorders.[85]
• Next-Generation Agents: The pharmaceutical pipeline includes the development of next-generation orexin modulators. This includes new antagonists with refined pharmacokinetic profiles designed for specific indications, as well as the development of orexin receptor agonists as a potential treatment for narcolepsy and other disorders of hypersomnolence.[88]

The diverse range of these clinical investigations highlights an emerging theme: suvorexant is being repositioned from a treatment for primary insomnia to a specialized hypnotic for insomnia secondary to complex medical and psychiatric conditions. Its non-GABAergic mechanism may offer a superior safety profile in these vulnerable populations, where traditional hypnotics could exacerbate comorbidities (e.g., cognitive fog in AD, respiratory depression in patients on opioids, or abuse potential in OUD).

Conclusion and Clinical Recommendations

Synthesis of the Risk-Benefit Profile

Suvorexant is an effective and mechanistically novel treatment for insomnia, offering a distinct alternative to traditional GABAergic hypnotics. Its primary benefit lies in its targeted suppression of the brain's wakefulness system, which improves both sleep onset and maintenance, often with a lower risk of physical dependence and withdrawal compared to older agents. This benefit is supported by robust clinical trial data showing sustained efficacy for up to one year.

However, this benefit is counterbalanced by a unique and significant risk profile. The drug's efficacy, while statistically significant, is often perceived as clinically modest in terms of absolute gains in sleep time. The most prevalent risk is dose-dependent next-day impairment of alertness and motor coordination, a direct consequence of its 12-hour half-life. More distinctively, suvorexant is associated with a profile of neuropsychiatric adverse events—including intensely vivid dreams, sleep paralysis, and hallucinations—that are a direct pharmacological mimicry of narcolepsy symptoms. Furthermore, its potential to worsen depression or trigger suicidal ideation in vulnerable individuals is a serious concern, likely linked to the orexin system's role in mood regulation. The high financial cost and lack of a generic alternative also present a substantial barrier to its use.[19] While one economic analysis from Japan suggested it could be cost-effective compared to zolpidem, this conclusion was highly sensitive to assumptions about fracture risk and may not be generalizable.[92]

Recommendations for Optimal Clinical Use

Based on the comprehensive analysis of its properties, the following recommendations are provided to guide the optimal and safe clinical use of suvorexant:

Patient Selection:

• Suvorexant should be considered a second-line or third-line agent for insomnia, reserved for patients who have failed or are not suitable candidates for non-pharmacological interventions like Cognitive Behavioral Therapy for Insomnia (CBT-I) and first-line pharmacotherapies.[19]
• Ideal candidates are adults with prominent sleep maintenance insomnia who have either not tolerated GABAergic agents or for whom the risks of dependence associated with those agents are a primary concern.
• Crucial Pre-Screening: A thorough psychiatric history is mandatory. Patients with a current or past diagnosis of major depression, anxiety disorders, or a history of suicidal ideation should be considered high-risk. If suvorexant is used, it must be with extreme caution and close monitoring. The drug is contraindicated in patients with narcolepsy.

Dosing and Administration:

• Start Low, Go Slow: Therapy should always be initiated at the lowest recommended dose of 10 mg.[30]
• Titrate to Lowest Effective Dose: The dose should only be increased to 15 mg or 20 mg if the 10 mg dose is well-tolerated but ineffective. The maximum dose of 20 mg should not be exceeded.[36]
• Special Consideration: A more conservative dosing strategy (e.g., a lower maximum dose) should be strongly considered for obese female patients due to their significantly higher drug exposure and increased risk of dose-related adverse events.[5]
• Administration Instructions: Counsel patients to take the medication on an empty stomach within 30 minutes of bedtime and only when they can ensure at least a 7-hour opportunity for sleep.[19]

Patient Counseling:

• Set Realistic Expectations: Inform patients that the primary goal is improved sleep maintenance and that the onset of sleep may not be as rapid as with other hypnotics.
• Warn About Key Risks: Education is paramount. Patients must be explicitly warned about:
• The high potential for next-day drowsiness and impaired driving ability, especially with the 20 mg dose.
• The risk of complex sleep behaviors, and the need to discontinue the drug immediately if they occur.
• The possibility of experiencing unique side effects like sleep paralysis, vivid dreams, or hallucinations.
• The critical importance of reporting any new or worsening symptoms of depression or suicidal thoughts to their prescriber without delay.
• Review Concomitant Medications: Advise patients to avoid alcohol and to report all other medications, including over-the-counter products like acetaminophen and supplements like St. John's wort, due to the high potential for interactions.

Monitoring:

• If a patient's insomnia does not improve within 7 to 10 days of treatment, they should be re-evaluated for underlying medical or psychiatric conditions that may be causing or exacerbating their sleep disturbance.[21]
• Regularly monitor for both continued efficacy and the emergence of adverse effects, with a particular focus on neuropsychiatric symptoms, throughout the duration of treatment.

Works cited

1. Suvorexant - Wikipedia, accessed August 8, 2025, https://en.wikipedia.org/wiki/Suvorexant
2. suvorexant | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 8, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2890
3. Suvorexant in insomnia: efficacy, safety and place in therapy - HPS Pharmacies, accessed August 8, 2025, https://www.hps.com.au/wp-content/uploads/2017/09/Knowledge-Centre-Volume-109-20170913.pdf
4. Suvorexant: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 8, 2025, https://go.drugbank.com/drugs/DB09034
5. Suvorexant - PMC - PubMed Central, accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4321430/
6. Clinical Policy: Suvorexant (Belsomra) - Reference Number: IL.PMN.109 Effective Date, accessed August 8, 2025, https://www.ilyouthcare.com/content/dam/centene/meridian/il/policies/PolicyUpdate5_18/YouthCare/IL.PMN.109%20Suvorexant%20(Belsomra)_HFS%20PDL%201Q21.pdf
7. Suvorexant, a Dual Orexin Receptor Antagonist for the Management of Insomnia - PMC, accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3989084/
8. What is the mechanism of Suvorexant? - Patsnap Synapse, accessed August 8, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-suvorexant
9. Suvorexant (MK-4305, CAS Number: 1030377-33-3) | Cayman ..., accessed August 8, 2025, https://www.caymanchem.com/product/22911/suvorexant
10. Belsomra (suvorexant) FDA Approval History - Drugs.com, accessed August 8, 2025, https://www.drugs.com/history/belsomra.html
11. Suvorexant | C23H23ClN6O2 | CID 24965990 - PubChem, accessed August 8, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Suvorexant
12. Australian public assessment report for Suvorexant (Belsomra) - Therapeutic Goods Administration (TGA), accessed August 8, 2025, https://www.tga.gov.au/sites/default/files/auspar-suvorexant-150411.pdf
13. en.wikipedia.org, accessed August 8, 2025, https://en.wikipedia.org/wiki/Suvorexant#:~:text=Suvorexant%20is%20a%20small%2Dmolecule,weight%20is%20450.92%20g%2Fmol.
14. Mechanism of action of suvorexant | CNS Spectrums | Cambridge ..., accessed August 8, 2025, https://www.cambridge.org/core/journals/cns-spectrums/article/mechanism-of-action-of-suvorexant/3FE3F0DF6DBED1825879FA5B9CC4F9BF
15. Suvorexant in insomnia: efficacy, safety and place in therapy - PMC - PubMed Central, accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4591519/
16. Belsomra Suvorexant - WVU School of Pharmacy, accessed August 8, 2025, https://pharmacy.hsc.wvu.edu/media/1889/belsomra-suvorexant.pdf
17. Belsomra vs. Ambien: How Do They Compare? - Verywell Health, accessed August 8, 2025, https://www.verywellhealth.com/belsomra-vs-ambien-which-is-best-for-you-8696403
18. Suvorexant: a promising, novel treatment for insomnia - PMC - PubMed Central, accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4772996/
19. Suvorexant (Belsomra) for Insomnia - AAFP, accessed August 8, 2025, https://www.aafp.org/pubs/afp/issues/2016/0615/p1016.html
20. Residual effects of low dose of suvorexant, zolpidem, and ramelteon ..., accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9515713/
21. Suvorexant: MedlinePlus Drug Information, accessed August 8, 2025, https://medlineplus.gov/druginfo/meds/a614046.html
22. Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia - PMC - PubMed Central, accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9886170/
23. Suvorexant - Therapeutic Goods Administration (TGA), accessed August 8, 2025, https://www.tga.gov.au/sites/default/files/auspar-suvorexant-150311-pi-01.docx
24. Belsomra and Alcohol/Food Interactions - Drugs.com, accessed August 8, 2025, https://www.drugs.com/food-interactions/suvorexant,belsomra.html
25. Belsomra (suvorexant) dosing, indications, interactions, adverse effects, and more, accessed August 8, 2025, https://reference.medscape.com/drug/belsomra-suvorexant-999859
26. Suvorexant: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 8, 2025, https://www.rxlist.com/suvorexant/generic-drug.htm
27. Profile of suvorexant in the management of insomnia - PMC - PubMed Central, accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4651361/
28. Belsomra - Drug Summary - PDR.Net, accessed August 8, 2025, https://www.pdr.net/drug-summary/belsomra-suvorexant-3605
29. Suvorexant Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 8, 2025, https://www.drugs.com/dosage/suvorexant.html
30. Reference ID: 5546332 - accessdata.fda.gov, accessed August 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/204569s010lbl.pdf
31. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials | Request PDF - ResearchGate, accessed August 8, 2025, https://www.researchgate.net/publication/267339309_Suvorexant_in_Patients_With_Insomnia_Results_From_Two_3-Month_Randomized_Controlled_Clinical_Trials
32. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials, accessed August 8, 2025, https://jcsm.aasm.org/doi/10.5664/jcsm.6116
33. Merck & Co., Inc. Insomnia Drug Shows Positive Phase III Results - BioSpace, accessed August 8, 2025, https://www.biospace.com/merck-and-co-inc-insomnia-drug-shows-positive-phase-iii-results
34. Suvorexant - LiverTox - NCBI Bookshelf, accessed August 8, 2025, https://www.ncbi.nlm.nih.gov/books/NBK547900/
35. Belsomra (Suvorexant) Dosage for Adults - GoodRx, accessed August 8, 2025, https://www.goodrx.com/belsomra/dosage
36. FULL PRESCRIBING INFORMATION Reference ID: 3610408 - accessdata.fda.gov, accessed August 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204569s000lbledt.pdf
37. Is suvorexant a better choice than alternative hypnotics? - PMC, accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4648222/
38. Belsomra (suvorexant): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed August 8, 2025, https://www.webmd.com/drugs/2/drug-166828/belsomra-oral/details
39. Belsomra: Dosing, contraindications, side effects, and pill pictures - epocrates online, accessed August 8, 2025, https://www.epocrates.com/online/drugs/7039/belsomra
40. FDA Approves BELSOMRA® (suvorexant) for the Treatment of Insomnia - Merck.com, accessed August 8, 2025, https://www.merck.com/news/fda-approves-belsomra-suvorexant-for-the-treatment-of-insomnia/
41. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BELSOMRA safely and effe - Merck.com, accessed August 8, 2025, https://www.merck.com/product/usa/pi_circulars/b/belsomra/belsomra_pi.pdf
42. Suvorexant: Insomnia Uses, Side Effects, Warnings - MedicineNet, accessed August 8, 2025, https://www.medicinenet.com/suvorexant/article.htm
43. Orexin/hypocretin in psychiatric disorders: present state of knowledge and future potential - ACNP, accessed August 8, 2025, https://acnp.org/wp-content/uploads/2017/10/OrexinHyprocretininPsychiatric.pdf
44. Neurobiology of the Orexin System and Its Potential Role in the Regulation of Hedonic Tone - PMC - PubMed Central, accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8870430/
45. Belsomra: Side effects, generic, dosage, and more - Medical News Today, accessed August 8, 2025, https://www.medicalnewstoday.com/articles/drugs-belsomra
46. Suvorexant - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed August 8, 2025, https://www.ncbi.nlm.nih.gov/books/NBK575922/
47. Belsomra Interactions: Other Medications, Alcohol, and More, accessed August 8, 2025, https://www.healthline.com/health/drugs/belsomra-interactions
48. Suvorexant (oral route) - Side effects & dosage - Mayo Clinic, accessed August 8, 2025, https://www.mayoclinic.org/drugs-supplements/suvorexant-oral-route/description/drg-20113017
49. Belsomra interactions: Other medications, alcohol, and more, accessed August 8, 2025, https://www.medicalnewstoday.com/articles/drugs-belsomra-interactions
50. Is Suvorexant (Belsomra) an equivalent to Zolpidem (Ambien)? - Dr.Oracle AI, accessed August 8, 2025, https://www.droracle.ai/articles/93186/suvorexant-ambien-equivalent
51. Belsomra vs Temazepam Comparison - Drugs.com, accessed August 8, 2025, https://www.drugs.com/compare/belsomra-vs-temazepam
52. Temazepam: will it help you get deep sleep? - Sleepstation, accessed August 8, 2025, https://www.sleepstation.org.uk/articles/medicines/temazepam/
53. Quantification of daridorexant, lemborexant, and suvorexant in whole blood using liquid chromatography–tandem mass spectrometry | Journal of Analytical Toxicology | Oxford Academic, accessed August 8, 2025, https://academic.oup.com/jat/advance-article/doi/10.1093/jat/bkaf032/8118879
54. Orexin antagonist - Wikipedia, accessed August 8, 2025, https://en.wikipedia.org/wiki/Orexin_antagonist
55. Different doses of dual orexin receptor antagonists in ... - Frontiers, accessed August 8, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1175372/full
56. Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis - PubMed, accessed August 8, 2025, https://pubmed.ncbi.nlm.nih.gov/40555730/
57. Comparison of efficacy and safety of dual orexin receptor antagonists lemborexant and daridorexant for the treatment of insomnia: a systematic review and meta-analysis - PubMed, accessed August 8, 2025, https://pubmed.ncbi.nlm.nih.gov/40133470/
58. Meta-Analysis Reveals Safety Concerns With FDA-Approved Dual Orexin Receptor Antagonists for Insomnia - NeurologyLive, accessed August 8, 2025, https://www.neurologylive.com/view/meta-analysis-reveals-safety-concerns-fda-approved-dual-orexin-receptor-antagonists-insomnia
59. Long-Term Data on Daridorexant, Suvorexant, and Lemborexant, accessed August 8, 2025, https://www.psychiatrictimes.com/view/long-term-data-on-daridorexant-suvorexant-and-lemborexant
60. Real-world evidence of the safety and efficacy profile of suvorexant ..., accessed August 8, 2025, https://pubmed.ncbi.nlm.nih.gov/31793350/
61. Real-world evidence of the safety and efficacy profile of suvorexant ..., accessed August 8, 2025, https://www.tandfonline.com/doi/pdf/10.1080/03007995.2019.1700361
62. Suvorexant for Insomnia Reviews - Drugs.com, accessed August 8, 2025, https://www.drugs.com/comments/suvorexant/for-insomnia.html
63. Belsomra (suvorexant) Reviews and User Ratings: Effectiveness ..., accessed August 8, 2025, https://reviews.webmd.com/drugs/drugreview-166828-belsomra-oral
64. Does Suvorexant cause Depression? Read What Users Report ..., accessed August 8, 2025, https://www.drugs.com/comments/suvorexant/sfx-depression.html
65. Does Suvorexant cause Anxiety? Read What Users Report - Drugs ..., accessed August 8, 2025, https://www.drugs.com/comments/suvorexant/sfx-anxiety.html
66. Anyone have any experience with Suvorexant/Belsomra? : r/ausadhd, accessed August 8, 2025, https://www.reddit.com/r/ausadhd/comments/1m8otby/anyone_have_any_experience_with_suvorexantbelsomra/
67. FDA updates insomnia medication info to include Alzheimer's study, accessed August 8, 2025, https://aasm.org/fda-updates-insomnia-medication-info-to-include-alzheimers-study/
68. Merck Receives Approval for BELSOMRA® (suvorexant) C-IV Label Update to Include Findings from Study of Insomnia in Patients with Mild-to-Moderate Alzheimer's Disease, accessed August 8, 2025, https://www.merck.com/news/merck-receives-approval-for-belsomra-suvorexant-c-iv-label-update-to-include-findings-from-study-of-insomnia-in-patients-with-mild-to-moderate-alzheimers-disease/
69. Effect of Suvorexant on Nocturnal Delirium in Elderly Patients with ..., accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6852677/
70. A Case of Persistent Delirium Resolved Promptly With Suvorexant - Psychiatrist.com, accessed August 8, 2025, https://www.psychiatrist.com/pcc/suvorexant-resolves-persistent-delirium/
71. Exploring the role of suvorexant in reducing delirium among older adults - News-Medical.net, accessed August 8, 2025, https://www.news-medical.net/news/20240829/Exploring-the-role-of-suvorexant-in-reducing-delirium-among-older-adults.aspx
72. Suvorexant Associated With Lower Delirium Rates in Some Hospitalized Older Adults, accessed August 8, 2025, https://www.hmpgloballearningnetwork.com/site/pcn/news/suvorexant-associated-lower-delirium-rates-some-hospitalized-older-adults
73. FDA-Approved Insomnia Drug Suvorexant Shows Promise in Reducing Alzheimer's-Related Proteins - MedPath, accessed August 8, 2025, https://trial.medpath.com/news/a7a6df9632ac7c35/fda-approved-insomnia-drug-suvorexant-shows-promise-in-reducing-alzheimer-s-related-proteins
74. Insomnia drug may lower levels of Alzheimer's proteins, accessed August 8, 2025, https://www.alzheimers.gov/news/insomnia-drug-may-lower-levels-alzheimers-proteins
75. Study Details | Suvorexant (Belsomra) for the Treatment of Bipolar Depression With Insomnia | ClinicalTrials.gov, accessed August 8, 2025, https://www.clinicaltrials.gov/study/NCT03764683?term=suvorexant&rank=9
76. Improving Sleep for Those with Opioid Use Disorder | Johns ..., accessed August 8, 2025, https://www.hopkinsmedicine.org/news/articles/2024/12/improving-sleep-for-those-with-opioid-use-disorder
77. Study Details | Double-blind Randomized Controlled Trial ..., accessed August 8, 2025, https://clinicaltrials.gov/study/NCT06162663
78. Suvorexant for the Treatment of Insomnia for Women with Breast Cancer - NCI, accessed August 8, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-08648
79. Study Details | Suvorexant in Insomnia Co-morbid With Fibromyalgia | ClinicalTrials.gov, accessed August 8, 2025, https://clinicaltrials.gov/study/NCT02684136
80. Orexin - Wikipedia, accessed August 8, 2025, https://en.wikipedia.org/wiki/Orexin
81. Appetite and Orexins - J-Stage, accessed August 8, 2025, https://www.jstage.jst.go.jp/article/jjpm/64/3/64_64.3_239/_article/-char/en
82. Rethinking the Role of Orexin in the Regulation of REM Sleep and Appetite - MDPI, accessed August 8, 2025, https://www.mdpi.com/2072-6643/15/17/3679
83. Orexins and appetite regulation | Request PDF - ResearchGate, accessed August 8, 2025, https://www.researchgate.net/publication/11018229_Orexins_and_appetite_regulation
84. Neurobiology of the Orexin System and Its Potential Role in the Regulation of Hedonic Tone, accessed August 8, 2025, https://www.mdpi.com/2076-3425/12/2/150
85. Orexin antagonists for neuropsychiatric disease: progress ... - Frontiers, accessed August 8, 2025, https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2014.00036/full
86. The Multifaceted Role of Orexin - Number Analytics, accessed August 8, 2025, https://www.numberanalytics.com/blog/orexin-neuropharmacology-neurological-disorders
87. Orexin - does it have a role in mental illness?, accessed August 8, 2025, https://www.wisdomlib.org/journals/131-orexin-does-have-role-mental-illness
88. Harmony Biosciences Reports Strong Q2 2025 Financial Results ..., accessed August 8, 2025, https://www.biospace.com/press-releases/harmony-biosciences-reports-strong-q2-2025-financial-results-and-reaffirms-2025-revenue-guidance-on-track-to-announce-fragile-x-topline-data-from-phase-3-registrational-trial-in-q3-2025
89. Orexin receptor antagonists for the treatment of insomnia - YouTube, accessed August 8, 2025, https://www.youtube.com/watch?v=21s8D-fQH3U
90. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics | Journal of Clinical Sleep Medicine, accessed August 8, 2025, https://jcsm.aasm.org/doi/10.5664/jcsm.7282
91. Belsomra cost 2025: Coupons and more - Medical News Today, accessed August 8, 2025, https://www.medicalnewstoday.com/articles/drugs-belsomra-cost
92. Cost-effectiveness analysis of suvorexant for the treatment of ..., accessed August 8, 2025, https://www.tandfonline.com/doi/pdf/10.1080/13696998.2018.1466710
93. Cost-effectiveness analysis of suvorexant for the treatment of Japanese elderly patients with chronic insomnia in a virtual cohort - PubMed, accessed August 8, 2025, https://pubmed.ncbi.nlm.nih.gov/29667471/